Docosahexaenoic Acid (DHA) Supplementation During Pregnancy Reduces the Risk of Preterm Birth in Threatened Preterm Labor
Docosahexaenoic Acid (DHA) Supplementation During Pregnancy Reduces the Risk of Preterm Birth in Threatened Preterm Labor
NCT ID: NCT06302023 Phase: PHASE2 Status: COMPLETED Enrollment: 60 Completion: 2024-10-07
Conditions
Pregnant Women Diagnosed With Threatened Preterm Labor
Interventions
Docosahexaenoic acid (DHA) 1000 mg
Summary
The goal of this clinical trial is to learn about the effects of Docosahexaenoic acid (DHA) in reducing the incidence of premature birth in threatened preterm labor
The main questions it aims to answer are:
- Can DHA supplementation reduce the incidence of premature birth in threatened preterm labor?
- How does DHA supplementation affect pregnancy outcomes? Participants were organized into two groups
- Group 1 (Intervention) Participants will be asked to take a DHA 1000mg per day
- Group 2 (control) Participant will not need to take a DHA
Primary Outcome
Number of Participants with preterm birth